{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:19:35Z","timestamp":1792279175005,"version":"4.4.0"},"reference-count":35,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. pediatr. gastroenterol. nutr."],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Experience with subcutaneous infliximab (SC\u2010IFX) use in pediatric inflammatory bowel disease (IBD) remains limited. We aimed to evaluate the clinical efficacy, tolerability, and cost\u2013benefit of SC\u2010IFX as a treatment for children with IBD in a real\u2010world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective, single\u2010center cohort study was conducted at the Children's Hospital at Westmead, Australia, from February to June 2024. Thirty\u2010three children aged 8\u201318 years with established IBD commenced SC\u2010IFX (120\u2009mg fortnightly). Assessments included clinical disease activity indices (Pediatric Crohn's Disease Activity Index [PCDAI]\/Pediatric Ulcerative Colitis Activity Index [PUCAI]), biochemical markers, and infliximab levels. Patient experience was assessed via questionnaires on quality\u2010of\u2010life (QOL) and treatment satisfaction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty\u2010one (31\/33) children completed treatment over a 12\u2010week follow\u2010up period. Median infliximab levels increased from 7.8\u2009ug\/mL (interquartile range [IQR]: 5.7\u201311) at baseline to 19.6 ug\/mL (IQR: 13.2\u201321.8) at Week 12 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Serum infliximab level &gt;20\u2009ug\/mL was seen in 48% of children at Week 12. Minimal change was observed in fecal calprotectin and clinical disease activity indices. High satisfaction rates with improved patient and caregiver QOL are described. Cost analyses indicated a potential for net institutional savings. Drug continuation was planned in 85% (28\/33) following the 12\u2010week study period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our experience suggests SC\u2010IFX may be an effective and well\u2010tolerated alternative to intravenous infliximab (IV\u2010IFX) in pediatric IBD. Median serum infliximab levels increased across over the study period. Use of SC\u2010IFX may offer a positive impact on patient and caregiver QOL, along with resource and cost saving benefits for healthcare systems. Larger\u2010scale studies are needed to validate these findings and optimize treatment protocols.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jpn3.70267","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T10:10:28Z","timestamp":1763460628000},"page":"439-446","source":"Crossref","is-referenced-by-count":6,"title":["Subcutaneous infliximab use in children with inflammatory bowel disease in an Australian center"],"prefix":"10.1002","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3615-2187","authenticated-orcid":false,"given":"Jessica A.","family":"Eldredge","sequence":"first","affiliation":[{"name":"Department of Gastroenterology The Children's Hospital at Westmead Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajneesh","family":"Kaur","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health University of Sydney Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cher Wei","family":"Chua","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology The Children's Hospital at Westmead Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trudy","family":"Chidgey","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology The Children's Hospital at Westmead Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Tano","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology The Children's Hospital at Westmead Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Singh","sequence":"additional","affiliation":[{"name":"Pharmacy Department The Children's Hospital at Westmead Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Barclay","sequence":"additional","affiliation":[{"name":"Pharmacy Department The Children's Hospital at Westmead Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabel","family":"Magoffin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology The Children's Hospital at Westmead Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal","family":"Thacker","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology The Children's Hospital at Westmead Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoma","family":"Dutt","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology The Children's Hospital at Westmead Sydney New South Wales Australia"},{"name":"Faculty of Medicine and Health University of Sydney Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward V.","family":"O'Loughlin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology The Children's Hospital at Westmead Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.02.068"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2023.12.013"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17822"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.08.011"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac053"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.05.006"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac119"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12664-023-01500-2"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11247296"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11195669"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2021.04.011"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa161"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002035"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002036"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.01.008"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.10.035"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac135"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003838"},{"issue":"1","key":"e_1_2_7_20_1","first-page":"A4","article-title":"OC5\u2005effectiveness and safety of switching to subcutaneous infliximab in paediatric inflammatory bowel disease patients on established intravenous biosimilar infliximab maintenance therapy: real world data from a regional cohort","volume":"15","author":"Gianolio L","year":"2024","journal-title":"Frontline Gastroenterol"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1536-4801.1991.tb10268.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20867"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21649"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.03.016"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-9-2"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904492"},{"key":"e_1_2_7_27_1","unstructured":"Australian Government Department of Health and Aged Care.Pharmaceutical Benefits Scheme\u2010 Infliximab medicine item listing [Internet].Australian Government;2025."},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad188"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16852"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11206173"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae127"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001123"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002631"},{"key":"e_1_2_7_34_1","unstructured":"Grifols Diagnostic Solutions Inc.Promonitor Control [Internet].Grifols;2025. Available from:https:\/\/www.diagnostic.grifols.com\/en\/patient\u2010testing\/clinical\u2010diagnostics\/biological\u2010drug\u2010monitoring\/promonitor\u2010control"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-020-5012-2"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.4929"}],"container-title":["Journal of Pediatric Gastroenterology and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jpn3.70267","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jpn3.70267","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jpn3.70267","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:50:09Z","timestamp":1776397809000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jpn3.70267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/jpn3.70267"],"URL":"https:\/\/doi.org\/10.1002\/jpn3.70267","archive":["Portico"],"relation":{},"ISSN":["0277-2116","1536-4801"],"issn-type":[{"value":"0277-2116","type":"print"},{"value":"1536-4801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]}}}